Valrubicin Suppliers & Bulk Manufacturers
Available Forms: Intravesical solution
Available Strengths: 40 mg/mL
Reference Brands: Valstar (USA),
Category:
Oncology Cancer Care
Valrubicin is available in Intravesical solution
and strengths such as 40 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Valrubicin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Valrubicin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is an anthracycline anticancer agent used primarily for the treatment of carcinoma in situ (CIS) of the urinary bladder, particularly in patients who have not responded adequately to Bacillus Calmette-Guérin (BCG) therapy and for whom immediate cystectomy is not suitable. It is a semisynthetic analog of doxorubicin and is designed for intravesical administration, meaning it is delivered directly into the bladder through a catheter. This localized method of administration allows the drug to act directly on cancerous cells lining the bladder while minimizing systemic exposure.
Valrubicin works by interfering with the DNA replication process of rapidly dividing cancer cells. As an anthracycline derivative, it inhibits nucleic acid synthesis and disrupts cellular functions that are essential for tumor growth and survival. This mechanism helps slow or stop the progression of malignant cells within the bladder lining.
The medication is typically supplied as an intravesical solution and administered under the supervision of healthcare professionals experienced in oncology treatment. Valrubicin plays an important role in bladder cancer management by providing a bladder-preserving therapeutic option for patients who are not candidates for more invasive surgical procedures.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing